Non Invasive Diabetes Therapy Market Cost Analysis, Strategy And Growth Factor Report By 2026
The role of
non-invasive therapy for diabetes market has been on a positive
growth path in healthcare industry since 2014. Though the
non-invasive therapy concept was brought way back in 1980, the market
has not gained much attention leading to development of fewer such
devices. DexCom's seven system and Medtronic's Guardian real-time
glucose monitoring system are two such products developed and
marketed worldwide. The influx of non-invasive therapy has reinforced
the diabetes market in various ways ranging from economical cost
incurred to patient treatment outcomes.
Many leading players
along with new entrants are venturing in the market to capitalize and
generate high ROI. As a result, noninvasive therapy market is
expected to witness double digit growth rate over the forecast
period.
The report covers
market analysis across regions – North America, Europe, Asia
Pacific, Latin America, Middle East and Africa.
Request For a
Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/54
Market
Dynamics:
The World Health
Organization projects diabetic population to reach 336 Mn by 2030
from 270 Mn in 2015. Increase in incidence rate of diabetic
population will demand for non-invasive medication is expected to
create favorable market opportunities for the players globally.
Moreover, improving healthcare access along with focus on R&D
could spur the overall non-invasive market size. Some companies are
engaged in development of non-invasive system on photonic technology
and occlusion spectroscopy technology.
The market will be
further driven by changing macroeconomics and consumer preference.
Healthcare expenditure has increased in developing regions. Large
consumer base along with changing lifestyle is expected to create
substantially new market opportunities for early entrants.
Regional
Analysis:
Among regions, North
America is expected to dominate the market throughout the forecast
period. Moreover, North America is expected to grow at a fastest rate
owing to high spending on R&D and presence of leading companies
in the region. Prevalence rate of diabetes is high compared to other
regions.
As per the initial
study carried out by CA, North America and Europe are expected to
account for over 65% of overall functional non-invasive diabetes
therapy market. Healthcare providers are seeking this technology to
manage the growing demand for diabetes. Growth in these regions is
expected to be further driven by macroeconomic factors. The region as
a whole spends over 5% of its GDP on research and GDP. Moreover,
healthcare spending is highest in this region with North America
accounting for 16.7% and Europe 10% of overall GDP in 2015.
Asia Pacific is
expected to be driven by China and India. According to International
Diabetes Federation, over 490 million people in China are suffering
from diabetes. Country is pushing toward healthcare reforms. Many
companies are emerging in the region. As a result,
Competition
Landscape:
Some key players
engaged in the market are Bio Tex, Calisto Medical, DexCom, Bayer,
ACON Laboratories, B. Braun Melsungen, etc.
Click To Read
More On Non
Invasive Diabetes Therapy Market
About Coherent
Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment